GSK (GSK) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citigroup | Maintained | Neutral | — | Jul 24, 2026 |
| Barclays | Downgraded | Equal-Weight → Underweight | — | Jan 6, 2026 |
| Jefferies | Initiated Coverage | Hold → Buy | — | Oct 27, 2025 |
| Jefferies | Downgraded | Buy → Hold | — | Nov 12, 2024 |
| Guggenheim | Downgraded | Buy → Neutral | — | Oct 31, 2024 |
| UBS | Downgraded | Buy → Neutral | — | Jul 8, 2024 |
| Jefferies | Maintained | Buy | $53.00 from $52.50 | Jul 2, 2024 |
| Goldman Sachs | Initiated Coverage | Neutral | $47.00 | May 30, 2024 |
| Guggenheim | Upgraded | Neutral → Buy | — | Mar 4, 2024 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $44.00 | Jan 23, 2024 |
| Jefferies | Upgraded | Hold → Buy | $48.00 from $38.50 | Jan 3, 2024 |
Frequently asked questions
Is GSK a buy, sell, or hold?
Analysts covering GSK currently average a Buy rating: 3 buy, 3 hold and 1 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on GSK?
On Jul 24, 2026, Citigroup maintained GSK at Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.